Literature DB >> 25148137

Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.

Jean-Marc Dumonceau1, Angelo Andriulli2, B Joseph Elmunzer3, Alberto Mariani4, Tobias Meister5, Jacques Deviere6, Tomasz Marek7, Todd H Baron8, Cesare Hassan9, Pier A Testoni4, Christine Kapral10.   

Abstract

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recommends routine rectal administration of 100 mg of diclofenac or indomethacin immediately before or after ERCP in all patients without contraindication. In addition to this, in the case of high risk for post-ERCP pancreatitis (PEP), the placement of a 5-Fr prophylactic pancreatic stent should be strongly considered. Sublingually administered glyceryl trinitrate or 250 µg somatostatin given in bolus injection might be considered as an option in high risk cases if nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated and if prophylactic pancreatic stenting is not possible or successful. 2 ESGE recommends keeping the number of cannulation attempts as low as possible. 3 ESGE suggests restricting the use of a pancreatic guidewire as a backup technique for biliary cannulation to cases with repeated inadvertent cannulation of the pancreatic duct; if this method is used, deep biliary cannulation should be attempted using a guidewire rather than the contrast-assisted method and a prophylactic pancreatic stent should be placed. 4 ESGE suggests that needle-knife fistulotomy should be the preferred precut technique in patients with a bile duct dilated down to the papilla. Conventional precut and transpancreatic sphincterotomy present similar success and complication rates; if conventional precut is selected and pancreatic cannulation is easily obtained, ESGE suggests attempting to place a small-diameter (3-Fr or 5-Fr) pancreatic stent to guide the cut and leaving the pancreatic stent in place at the end of ERCP for a minimum of 12 - 24 hours. 4 ESGE does not recommend endoscopic papillary balloon dilation as an alternative to sphincterotomy in routine ERCP, but it may be advantageous in selected patients; if this technique is used, the duration of dilation should be longer than 1 minute. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25148137     DOI: 10.1055/s-0034-1377875

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  133 in total

1.  The impact of prophylactic pancreatic stenting on post-ERCP pancreatitis: A nationwide, register-based study.

Authors:  Greger Olsson; Jeanne Lübbe; Urban Arnelo; Eduard Jonas; Björn Törnqvist; Lars Lundell; Lars Enochsson
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

2.  Suppository naproxen reduces incidence and severity of post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial.

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Zahra Taherzadeh; Homayoon Sokhanvar; Tolou Hasandokht
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  The revised Atlanta criteria more accurately reflect severity of post-ERCP pancreatitis compared to the consensus criteria.

Authors:  Xjnm Smeets; N Bouhouch; J Buxbaum; H Zhang; J Cho; R C Verdonk; Teh Römkens; N G Venneman; I Kats; J M Vrolijk; Gjm Hemmink; A Otten; Acitl Tan; B J Elmunzer; P B Cotton; Jph Drenth; Ejm van Geenen
Journal:  United European Gastroenterol J       Date:  2019-02-27       Impact factor: 4.623

4.  Efficacy and safety of the rotatable sphincterotome during ERCP in patients with prior Billroth II gastrectomy (with videos).

Authors:  Feng Zhu; Yaping Guan; Jing Wang
Journal:  Surg Endosc       Date:  2021-03-17       Impact factor: 4.584

5.  Endoscopic classification of the papilla of Vater. Results of an inter- and intraobserver agreement study.

Authors:  E Haraldsson; L Lundell; F Swahn; L Enochsson; J M Löhr; U Arnelo
Journal:  United European Gastroenterol J       Date:  2016-10-17       Impact factor: 4.623

Review 6.  Quality in endoscopy training-the endoscopic retrograde cholangiopancreatography case.

Authors:  Ivan Jovanovic; Klaus Mönkemüller
Journal:  Ann Transl Med       Date:  2018-07

7.  Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Yu Zhang; Xiaoling Ye; Xinyue Wan; Tao Deng
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

8.  History of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis and Acute Pancreatitis as Risk Factors for Post-ERCP Pancreatitis.

Authors:  Eiji Funatsu; Atsuhiro Masuda; Mamoru Takenaka; Takashi Nakagawa; Hideyuki Shiomi; Hayato Yoshinaka; Takashi Kobayashi; Arata Sakai; Yosuke Yagi; Masaru Yoshida; Yoshifumi Arisaka; Yoshihiro Okabe; Hiromu Kutsumi; Takeshi Azuma
Journal:  Kobe J Med Sci       Date:  2017-05-15

9.  No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.

Authors:  Hirotoshi Ishiwatari; Takahiro Urata; Ichiro Yasuda; Shimpei Matsusaki; Hiroyuki Hisai; Hiroshi Kawakami; Michihiro Ono; Takuji Iwashita; Shinpei Doi; Kazumichi Kawakubo; Tsuyoshi Hayashi; Tomoko Sonoda; Naoya Sakamoto; Junji Kato
Journal:  Dig Dis Sci       Date:  2016-07-22       Impact factor: 3.199

Review 10.  Is endoscopic papillary balloon dilatation really a risk factor for post-ERCP pancreatitis?

Authors:  Toshio Fujisawa; Koichi Kagawa; Kantaro Hisatomi; Kensuke Kubota; Atsushi Nakajima; Nobuyuki Matsuhashi
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.